The Americas Generics Producers: Where Are the Big Opportunities? provides newly researched company profiles and competitive intelligence on almost 20 leading generics producers (see full list below) operating in 10 key markets: Argentina, Brazil, Canada, Chile, Colombia, Mexico, Peru, Puerto Rico, United States, Venezuela.
We highlight opportunities for Asian firms such as Glenmark, which are keen to penetrate key Latin American generics markets such as Argentina via acquisitions. Furthermore, we evaluate how market penetration in Latin America will increase steadily as governments seek to reduce exposure to patented drugs.
The Americas Generics Producers: Where Are the Big Opportunities? also evaluates key industry trends and growth dynamics, and features BMI’s independent 5-year industry forecasts for each market to end-2012. Each of the 10 generics markets is also ranked according to the competitiveness of the regulatory and business operating environment, and growth potential of the generics segment over the 5-year forecast horizon.
BMI values the Americas' generic drug sector at US$41.8bn, and we forecast 12.7% year-on-year growth through 2012. The Americas Generics Producers: Where Are the Big Opportunities? examines the key drivers of this rapid growth (growing economies, cost-containment policies, ageing populations and the emergence of chronic diseases), and the opportunities arising for multinational and local generics producers alike.
The potential is impressive: BMI values the Americas' generic drug sector at US$5.2bn in 2008, and we forecast 12% year-on-year growth through 2012. The Report examines the key drivers of this rapid growth (growing economies, cost-containment policies, young populations and the emergence of chronic diseases), and the opportunities arising for multinational and local generics producers alike in each market.
But growth potential is not uniform across the region. Indeed, of the 10 markets covered in the Report, we believe that Brazil’s offers the best prospects and will likely increase in size by 16% this year. Mexico, Peru and Colombia also offer attractive markets, with FTAs in all states suggesting that recent improvements in the regulatory environment should continue over the forecast period.
Furthermore, there are risks. While we remain confident that the Americas' generics drug market will continue to expand, we also evaluate the threat posed by similares – low-cost copy drugs that are non-bio equivalents to more expensive patented. Specifically, we ask whether low cost – and more reliable – generics can head-off the threat posed by other budget alternatives in this highly cost-conscious market.
List of almost 20 leading generics companies profiled in The Americas Generics Producers: Where Are the Big Opportunities?:
Argentina (Laboratorios Bago, Laboratorios Roemmers)
Brazil (Medley, Eurofarma, EMS Sigma, Ache/Biosintetica, Novartis)
Canada (Apotex)
Chile (Laboratorios Maver, Laboratorios Andromaco, Laboratorios Chile (LabChile))
Colombia (Lafrancol, Tecnoquimicas)
Mexico (Liomont, Novartis Farmaceutica)
Peru (Farmaindustria)
Venezuela (Grupo Farma, Elmor, Novartis)
| 
